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Abstract
Fibroblasts from 16 patients with known K-L-iduronidase gene mutations and different clinical phenotypes of
mucopolysaccharidosis type I (MPS I) were investigated in order to establish genotype/phenotype correlations. Enzyme
kinetic studies were performed using the specific K-L-iduronidase substrate iduronosyl anhydro[1-3H]mannitol-6-sulfate.
Specific residual enzyme activities were estimated using the kinetic parameters and an immunoquantification assay which
determines levels of K-L-iduronidase protein. Cells were cultured in the presence of [35S]sulfate and the in vivo degradation of
accumulated labelled glycosaminoglycans measured after different chase times. Residual enzyme activity and different
amounts of residual enzyme protein were present in extracts from 9 of 16 cell lines covering a wide spectrum of clinical
severity. Catalytic capacity, calculated as the product of kcat/Km and ng iduronidase protein per mg cell protein, was shown in
most cases to be directly related to the severity of clinical phenotype, with up to 7% of normal values for patients with the
attenuated form of MPS I (Scheie) and less than 0.13% for severely affected patients (Hurler). In vitro turnover studies
allowed further refinement of correlations between genotype and phenotype. Scheie disease compared to Hurler disease
patients were shown to accumulate smaller amounts of glycosaminoglycans that were also turned over faster. A combination
of turnover and residual enzyme data established a correlation between the genotype, the biochemical phenotype and the
clinical course of this lysosomal storage disorder. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mucopolysaccharidosis type I (MPS I, McKusick
252800) is an autosomal recessive condition caused
by a de¢ciency of K-L-iduronidase (IDUA; EC
3.2.1.76). IDUA is required for the lysosomal degra-
dation of the glycosaminoglycans heparan and der-
matan sulfate. Impaired degradation of these glyco-
saminoglycans leads to their lysosomal storage, their
urinary excretion and the progressive deterioration of
cells, tissues and organs [1]. Patients with the classi-
cal, severe Hurler disease are often diagnosed within
their ¢rst year of life and usually die in their second
decade. They su¡er from skeletal deformities, joint
contractions, hepatosplenomegaly, corneal clouding
and severe mental retardation. Patients with the at-
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tenuated clinical form of MPS I, Scheie disease, may
be recognised in their early teens, have normal intel-
ligence, attenuated skeletal symptoms, and poten-
tially, a normal lifespan. However, cardiac impair-
ment and spinal cord compression in Scheie
patients can cause serious clinical problems later in
life. Forms of MPS I with intermediate clinical phe-
notypes (Hurler/Scheie) that include normal or re-
duced intelligence with marked somatic symptoms
have also been described. After isolation and charac-
terisation of the IDUA enzyme protein [2^4] and
cloning of the cDNA [5] and the gene [6], the analysis
of the primary disease causing mutations became
possible. Two common missense mutations, W402X
[7] and Q70X [8] together account for about 60% of
disease alleles in Caucasians. However, the frequen-
cies of these two mutations were shown to vary in
di¡erent European regions [9]. Some other gene al-
terations were found recurrently [10,11]; many others
are rare. In a recent review article, Scott et al. [12]
summarised more than 40 di¡erent gene mutations,
demonstrating the vast genetic heterogeneity of this
disease. Prediction of a patient’s phenotype from a
full genotype is di⁄cult. Patients with missense mu-
tations or frame-shifts that lead to truncated pro-
teins, probably without residual activity, generally
show the typical, severe Hurler phenotype. However,
among patients with missense mutations, clinically
severe and attenuated phenotypes have been ob-
served, possibly re£ecting the position and nature
of the mutations [12]. In this paper, we describe in-
vestigations that attempt to relate residual IDUA
activity, kinetic parameters, and the ability of cul-
tured cells to turn over glycosaminoglycans, to the
severity of a patient’s clinical phenotype and geno-
type.
2. Materials and methods
2.1. Cell lines
Fibroblast lines 56, 72, 81, 91, 99 and 100 of pa-
tients with MPS I originated from The European
Human Cell Bank, Rotterdam, The Netherlands.
Their underlying gene defects as well as those of
the MPS I patient cell lines 4, 59 and 103 have
been described in detail elsewhere [9,13]. They were
selected to cover the known spectrum of clinical phe-
notypes. Cell lines 3300, 3542 and 3878 were normal
controls. Cell lines 3061, 3125, 3481, 3568 and 3674
originated from patients with classical Hurler dis-
ease, were diagnosed at the Department of Chemical
Pathology at the WCH, Adelaide, and shown to have
the common missense mutations Q70X and W402X,
whereas cell lines 283, 2474 and 2730 originated from
clinically less severe MPS I patients and were also
diagnosed at the WCH.
2.2. Cell culture
Patient and control ¢broblasts were grown in basal
modi¢ed Eagle’s medium (BME) containing 10% (v/
v) fetal calf serum (FCS), 50 units/ml of penicillin
and 50 Wg/ml of streptomycin. Before any of the cells
were assayed for IDUA activity, all cells were grown
for a minimum of three changes of media containing
heat inactivated (2 h at 55‡C) FCS (HIFCS) over 6
to 8 days. This step was used to remove bovine
IDUA that, if present, could contribute IDUA activ-
ity to cells in culture.
2.3. Enzyme kinetics
For assay of IDUA activity, cultured ¢broblasts at
con£uence in one 75-cm2 plastic bottle were har-
vested using trypsin and the cells washed three times
with 0.15 M NaCl. The cell pellet was suspended in
100 Wl 0.1% (v/v) Triton X-100 and disrupted by ¢ve
freeze^thawing cycles in a solid CO2/ethanol mixture.
The method of Lowry et al. [14] was used to estimate
protein content and 15^20 Wg protein used in each
incubation to determine IDUA activity. The cell ho-
mogenate was incubated for 1 h with 5 Wl Dowex-2
resin in 0.2 M sodium formate bu¡er (pH 3.6) on ice
to remove endogenous accumulated substrates, then
the resin was removed by ¢ltration through a nylon
¢lter. Aliquots of the cell extracts were stored at
380‡C and thawed only for the IDUA assay.
IDUA activities in these extracts were assayed in
microtitre plates using di¡erent concentrations of
K-L-iduronosyl anhydro-[1-3H]mannitol 6-sulfate
(IMS). Each reaction mixture (12 Wl) contained 3 Wl
0.2 M sodium formate bu¡er (pH 3.6), 3 Wl 5 mg/ml
BSA in 0.1% (v/v) Triton X-100, 5 Wl cell extract
diluted with 0.1% (v/v) Triton X-100 to contain
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15^20 Wg cell protein, and 1 Wl of IMS substrate. For
normal control cells, approximately 1 Wg cell protein
was used per assay. Five Wl BSA (5 mg/ml in 0.1% (v/
v) Triton X-100) instead of cell extract served as
blank. The IMS substrate concentrations used
were: 10.4 WM, 13.8 WM, 20.8 WM, 27.5 WM, 41.6
WM, 55.0 WM and 83.3 WM. Duplicates were used
for each extract with each IMS concentration. Incu-
bation was for 20 h at 32‡C. Substrate and product
in the assay mixtures were separated by high-voltage
electrophoresis in 4% (v/v) formic acid for 50 min at
3000 V [15]. After determining positions of substrate
(IMS) and product ([1-3H]mannitol 6-sulfate) peaks
by scanning the paper strips, appropriate segments
were eluted with water, scintillation £uid added and
radioactivity measured in a scintillation counter.
IDUA activities (pmol/min per mg cell protein)
were calculated for the di¡erent substrate concentra-
tions and Michaelis^Menten kinetics established. Km
and Vmax values were calculated using Lineweaver^
Burk plots and a linear-regression analysis. A molec-
ular mass of 65 000 [2] was used to calculate the
turnover number kcat. Catalytic e⁄ciency was calcu-
lated as the ratio kcat/Km, the catalytic capacity as the
product of the catalytic e⁄ciency and the amount of
IDUA protein as ng per mg cell protein [16].
2.4. Immunoquanti¢cation
The immunoquanti¢cation assay to determine the
amount of IDUA protein present in patient ¢bro-
blast extracts was done as described previously [16].
Brie£y, microtitre plates were coated with a polyclo-
nal antibody against IDUA and IDUA protein cap-
tured from cell homogenates. A monoclonal anti-
body (Id1A) and peroxidase-labelled second
antibody were used to detect the captured IDUA
protein. For each assay, a standard curve was gen-
erated from a serial dilution of a standardised extract
with known IDUA content. For MPS I ¢broblast
lines, cells of two con£uent 75-cm2 bottles were tryp-
sinised, and washed three times with PBS; cell pellets
were suspended in 200 Wl 0.02 M Tris^HCl bu¡er
(pH 7.0) containing 0.5 M NaCl and subjected to
six cycles of freeze^thawing. Extracts were centri-
fuged at 6000Ug for 5 min to remove cell debris
before application of the supernatant to the micro-
titre plate. Fifty Wl of undiluted extract from each
cell line (containing 1^7 mg cell protein/ml) was as-
sayed in triplicate. The extracts of cell lines 81 and
100 contained considerable amounts of IDUA pro-
tein and had to be diluted to be within the range of
the assay.
2.5. In vitro substrate turnover assay
Medium was removed from con£uent ¢broblasts
in 75-cm2 £asks and preincubation was performed
for 2 h with sulfate-free Ham’s F12 medium with
10% (v/v) HIFCS. Six ml of the same medium with
20 WCi/ml of [35S]sulfate per £ask were applied and
the cells incubated for 72 h at 37‡C, 5% CO2. The
pH was controlled during incubation and was con-
stant at about 7.2. After removal of the uptake me-
dium, cell layers were rinsed three times with PBS,
harvested by trypsinisation, and centrifuged. Cell pel-
lets were resuspended in 16 ml BME (containing 10%
v/v HIFCS). Two-ml aliquots of the cell suspensions
were seeded into wells of 6-well plates for duplicates
at di¡erent chase times. Two 2-ml aliquots of each
sample were processed directly (time zero chase).
After 6, 24 or 48 h, chase media were removed, the
cells were rinsed with PBS, trypsinised, centrifuged,
and resuspended in 400 Wl 20 mM Tris^HCl bu¡er
(pH 7.0) containing 0.5 M NaCl. Cells were extracted
by six cycles of freeze^thawing. Free sulfate was sep-
arated from high-molecular-mass material in cell ex-
tracts and chase media using PD10 columns (Sepha-
dex G25, Pharmacia) eluted with a bu¡er containing
4 M guanidinium hydrochloride, 0.1 M Na2SO4, 0.05
M Tris (pH 7) and 0.5% (v/v) Triton X-100. After
application of the samples, 500-Wl fractions were col-
lected, and 500 Wl 70% (v/v) ethanol was added to
each fraction. Samples were counted with 4 ml scin-
tillation cocktail. While the [35S]sulfate-labelled high-
molecular-mass material (mainly glycosaminogly-
cans) appeared in the void volume, free sulfate was
eluted as a clearly separated peak. Counts of the
relevant fractions were added, and amounts of gly-
cosaminoglycans and free sulfate were calculated for
cell extracts and medium.
2.6. Uptake and turnover studies with decorin/biglycan
[35S]Sulfate-labelled decorin/biglycan was prepared
by incubation of cartilage from eight cow hocks with
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[35S]sulfate, the extracellular material extracted, sub-
jected to CsCl gradient centrifugation and desalted
on a column of Sephadex G50. Analysis of the ex-
cluded fractions, total of 1 200 000 cpm, demon-
strated that all of the radiolabelled material ran
with decorin and biglycan on 4^20% polyacrylamide
gradient gels. Cells, lines 81 (R383H/R383H), 3125
(W402X/W402X) and a normal control, were seeded
into wells of 6-well plates, and cultured in Ham’s F12
medium with 10% (v/v) HIFCS until the cells reached
con£uence. Each well was given 1 ml of fresh me-
dium containing 20 000 cpm of the decorin/biglycan
preparation for 47 h, the medium changed, and the
cells incubated for 0, 4, 24 and 48 h. Cells and me-
dium were assayed for radioactivity.
3. Results
3.1. Enzyme kinetics and immunoquanti¢cation
Using di¡erent concentrations of the IMS sub-
strate, it was possible to establish Km and Vmax val-
ues for 11 of the 16 MPS I ¢broblast extracts (Table
1). IDUA activity was not detected in cell lines which
had early stop codons in both of their IDUA genes
(cell lines 3061, 3125, 3481, 3674). IDUA protein
could not be detected by immunoquanti¢cation assay
in these cell lines. For two lines (56, 103), IDUA
kinetic parameters could be estimated but IDUA
protein was not detected. Cell line 4, with a splicing
mutation and a missense mutation (W626R), had
non-detected IDUA activity and protein values.
Although the R383H IDUA in cell line 81 showed
a normal Km value, the Vmax value was less than 10%
of the normal value. The amount of IDUA protein
was one-third of the normal control. Surprisingly,
cell line 100, with a termination mutation on one
IDUA allele and the missense R89W allele on the
other, had IDUA protein levels approximately ¢ve
times higher than normal controls. The Km value of
cell line 100 was approximately four times higher
than in the normal controls but still close to the
upper limit of the range of 22 controls [16], while
Vmax was about 70 times lower than in the controls.
Cell lines 2474, 2730, 283, 72 and 59 had a premature
Table 1
Iduronidase enzyme kinetics and immunoquanti¢cation
Cell
line


























3542 wild-type wild-type N 34.6 339 30 11.3 735 21.2 636.9
3300 wild-type wild-type N 31.1 288.2 30 9.6 624 20.1 602.4
81 R383H R383H S 29.4 19 10.9 1.8 114 3.9 42.0
100 Q70X R89W S 114 4.6 149.5 0.03 2 0.02 2.6
2474 W402X 678-7gCa S 31.6 1.2 0.04 30 1950 61.7 2.5
99 L490P L490P H/S 83 3.5 0.7 5.1 334 4.0 2.7
91 A327P 1995del12 H/S 132 2.7 0.4 6.8 438 3.3 1.3
2730 W402X R89Q H/S 65.4 0.5 0.5 1 65 1.0 0.5
283 W402X P533R H/S 114 0.4 0.3 1.2 78 0.7 0.2
103 M504T M504T H/S 67.5 1.5 nd ud ud ud ud
4 W626R 474-2aCg H/S nd nd nd ud ud ud ud
72 W402X R489P H 151.2 1.9 0.9 2.3 148 1.0 0.8
59 W402X G51D H 575 3.0 1.4 2.2 141 0.2 0.3
56 134del12 134del12 H 209 3.5 nd ud ud ud ud
3061 W402X W402X H nd nd nd ud ud ud ud
3125 W402X W402X H nd nd nd ud ud ud ud
3481 Q70X Q70X H nd nd nd ud ud ud ud
3674 Q70X W402X H nd nd nd ud ud ud ud
aN, normal control; S (Scheie), attenuated phenotype; H/S (Hurler/Scheie), intermediate clinical severity; H (Hurler), clinically severe;
nd, not detected (Km, Vmax : measured values did not result in Michaelis^Menten kinetics ; IDUA protein: no enzyme protein detect-
able); ud, undetermined (cannot be calculated).
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stop codon (W402X) in one of their IDUA alleles
but di¡erent mutations in the other allele. These
cell lines had measurable IDUA kinetic parameters
and IDUA protein presumably derived from their
non-W402X allele.
Patient 2474 has a point mutation in intron 5 of
the IDUA gene (678-7gCa) that creates an alterna-
tive splice site while the normal site is maintained.
Thus, any IDUA protein translated from normally
spliced transcripts should be completely normal. In-
deed, a normal Km value was measured. However,
the di¡erences between 2474 and normal cells in
turnover number and catalytic e⁄ciency can be the
result of experimental variation in measurement of
such low levels of iduronidase.
Table 1 summarises the results and also gives the
values for the catalytic e⁄ciencies and catalytic ca-
pacities. The catalytic capacity shows a sharp decline
from normal cells to MPS I cells, although di¡eren-
ces can be seen among the cell lines from patients
with di¡erent mutations and di¡erent clinical pheno-
types.
3.2. In vitro accumulation and degradation of
glycosaminoglycans
Five di¡erent ¢broblast lines were selected for in
vitro accumulation and degradation of glycosamino-
glycans, two from Hurler disease patients (cell line
3568: W402X homozygote; cell line 59: W402X,
G51D), two from Scheie disease patients (cell line
81: R383H homozygote; cell line 100: Q70X,
R89W) and the normal control line 3978. After in-
cubation with [35S]sulfate, the cells were trypsinised
and washed before seeding into 6-well plates. At the
zero time point, all accumulated high-molecular-
mass material and free sulfate was intracellular or
tightly linked to the cell surface. The duplicates for
di¡erent chase times were seeded into 6-well plates
with fresh unlabelled medium and the amount of
high-molecular-mass material and free sulfate was
measured in the chase media as well as in the cell
extracts. At the zero time point, di¡erent cells had
accumulated di¡erent amounts of high-molecular-
mass glycosaminoglycans. During the chase time,
the amount of this material declined in all cells
(Fig. 1). For the cell line 3568 there was a sharp
decline during the ¢rst 24 h of chase, but the curve
£attened during further incubation. At the same
time, 95% of the counts appeared as free sulfate in
the medium and only a small, relatively constant
amount remained within the cells (not shown).
Only a small amount of high-molecular-mass materi-
al occurred outside the cells during the chase. When
the amount of material accumulated at time point
zero was set to 100%, the control line quickly de-
clined to a plateau of about 40% (Fig. 2). The two
Scheie lines which had accumulated much less radio-
Fig. 2. Turnover of accumulated glycosaminoglycans. Counts
accumulated in the cells after 35S incubation were set to 100%.
Symbols: see legend to Fig. 1.
Fig. 1. Amount of 35S (cpm) present in high-molecular-mass
material (GAGs, glycosaminoglycans) in cell extracts plus me-
dium of ¢ve cell lines after di¡erent chase times. (S) MPS I se-
vere (W402X/W402X); (b) MPS I severe (W402X/G51D); (8)
MPS I attenuated (Q70X, R89W); (R) MPS I attenuated
(R383H/R383H); (F) normal control.
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activity than the Hurler lines also declined quickly,
reaching 50% of degradation at 30 and 45 h, respec-
tively. By extrapolation, the two Hurler lines had
half-degradation times of 4 to 6 days. Longer chase
times were not performed, as the metabolism of the
cells was assumed to slow down without change of
medium or subdivision, and as an equilibrium be-
tween new synthesis and degradation may be
reached. Such an equilibrium may be reached after
24 h for the normal cells.
3.3. Uptake and turnover studies with decorin/biglycan
Cell lines 81 and 3125 were shown to accumulate
(70 and 360 cpm, respectively) radioactivity com-
pared to normal control (20 cpm). After a 48 h chase
40 cpm remained in cell line 81 and 150 cpm in cell
line 3125 with 15 cpm in the normal control. Radio-
activity lost from the cells during the chase period
was recovered in the medium.
4. Discussion
Fibroblast cell lines investigated in the present
study originated from patients with di¡erent clinical
severities of mucopolysaccharidosis type I. IDUA
de¢ciency was established with routine diagnostic as-
says using the substrates IMS, phenyl K-iduronide or
4-methlyumbelliferyl K-L-iduronide. Apart from one
exception, none of the patients showed a signi¢cant
level of residual IDUA activity. The exception was
cell line 81, with 2% to 5% residual activity (W.J.
Kleijer, personal communication). As basis for eluci-
dation of genotype/phenotype correlations, patho-
genic alterations of the IDUA gene were determined
[8,9,13,17]. Fibroblasts of patients with the common
missense mutations Q70X and W402X served as
references for the most severe form of Hurler disease.
It is known that mRNAs with such early stop codons
have a reduced stability [9]. Any enzyme protein that
is eventually translated from these transcripts will be
truncated and predictably have impaired processing,
reduced stability, and be enzymatically inactive. Thus
these mutations can be considered to be functional
‘null’ mutations. Although exchange of only one
amino acid can severely impair enzyme function,
missense mutations are the ones most likely to be
compatible with residual IDUA activity. Two of
the missense mutations investigated, R383H and
R89W, were found in patients with the attenuated
‘Scheie’ phenotype. Since R89Q also led to an atte-
nuated clinical phenotype (Hurler/Scheie) when in
combination with W402X [17], an arginine in posi-
tion 89 is probably not vital for enzyme function.
R489P and G51D caused a severe phenotype, at least
in combination with W402X on the other allele,
while L490P, M504T (homozygous), W626R (with
475-2aCg on the other allele) and A327P (with
1995del12) led to a clinical phenotype with inter-
mediate severity. It should be noted that since
A327P in homozygous form or with a large deletion
on the other allele causes the classic Hurler syndrome
phenotype, the attenuated phenotype in the patient
investigated here may have been due to the allele
with the in frame deletion. A Hurler patient with a
deletion of four amino acids (134 del12) was included
in the study, as it has been speculated that the dele-
tion could be compatible with a functional signal
peptide [12]. Although some residual activity was
seen in this particular patient, there was no measur-
able IDUA protein, making it probable that the de-
letion does severely impair synthesis, transport and/
or processing of IDUA.
To explain the vast clinical diversity among pa-
tients with no or almost no detectable IDUA enzyme
activity in diagnostic assays, di¡erences in the in vivo
capacity to turn over glycosaminoglycans can be
postulated. Therefore, our intention was to look for
residual enzyme activity more carefully, to analyse
kinetic parameters and to quantify the amounts of
mutant enzymes. As a⁄nity of the radiolabelled sub-
strate IMS is known to be about four times higher
than that of the £uorogenic substrate [18] and as
residual activity was demonstrated with IMS in other
patients with Scheie disease [19], this was the sub-
strate of choice. While there was no detected residual
IDUA activity in the patients with termination mu-
tations and in one Hurler/Scheie patient with a point
mutation and a frame-shift inducing splice site muta-
tion, Km and Vmax values could be estimated for
other patients covering the whole clinical spectrum.
The R383H enzyme has a normal substrate a⁄nity
but a reduced maximal velocity (Vmax); a reduced
stability may be re£ected in the ¢nding that the pro-
tein amount was reduced to one-third of the amount
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in controls. In three Scheie patients, four Hurler/
Scheie patients and two Hurler patients, residual
IDUA protein was measurable, so that turnover
numbers, catalytic e⁄ciency and catalytic capacity
could be calculated. The latter value especially al-
lowed biochemical discrimination between patients
with di¡erent clinical severities. While the Scheie pa-
tients had 0.4% to 7% of the normal catalytic ca-
pacity, the Hurler/Scheie patients had 0.03% to
0.4% of normal or no catalytic capacity. The cell
lines of Hurler patients had below 0.13% of normal
capacity. However, the catalytic capacity was about
the same in the Scheie cell line 100 and in the Hurler/
Scheie cell line 99, and the two Hurler lines 72 and 59
had slightly higher capacities than the two Hurler/
Scheie lines 2730 and 283. Moreover, no catalytic
capacity was measured for cell lines from intermedi-
ately as well as from severely a¡ected patients. Be-
cause of such overlapping values, these phenotypes
cannot be clearly discriminated using this parameter
only.
Slight di¡erences of the in vivo turnover capacity
of natural substrate that do only occur in the living
cell may still account for the di¡erences in pheno-
type. This possibility prompted us to study in vitro
turnover of accumulated substrates. Cell lines 81 and
100 from Scheie patients, besides accumulating con-
siderably less radiolabelled glycosaminoglycan than
cell lines derived from Hurler patients, also were
able to degrade half of the accumulated material
within 30 to 48 h. Although cell line 81 had a 16
times higher catalytic capacity when compared to
cell line 100, they did not di¡er to the same extent
in the in vitro experiment. This suggests that there
may be factors in the natural environment within the
lysosome that favour the turnover of glycosamino-
glycans and cannot be measured in crude cell ex-
tracts. It is unknown whether the unusually high
amount of mutant IDUA in cell line 100 contributes
to its elevated in vitro turnover capacity. It is also
interesting to note that the low, just measurable cat-
alytic capacity in cell line 59, from a Hurler syn-
drome patient, enabled signi¢cant in vitro turnover
since this cell line only accumulated half of the ma-
terial found in the W402X homozygote.
The uptake and turnover studies using radiola-
belled decorin/biglycan supported the ¢ndings of
the in vitro labelling studies. That is, compared to
normal controls, W402X/W402X cells accumulate
proteoglycans and turn them over at a considerably
lower rate than R383H/R383H cells from a clinically
attenuated MPS I patient.
In conclusion, a combination of residual IDUA
activity kinetic parameters, immunoquanti¢cation
of IDUA mutant protein and in vitro turnover stud-
ies has enabled correlation of the biochemical phe-
notype of a patient with a given genotype. Such in-
vestigations of cells from young patients with
previously undetected mutations can be used to pre-
dict clinical outcome, and thus assist in decisions
concerning choice of which therapeutic procedure
to use for individual patients.
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